Eoquin (Bladder Cancer) - Analysis and Forecasts to 2020


#28408

25pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Eoquin (Bladder Cancer) Analysis and Forecasts to 2020 provides Eoquin global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Eoquin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Eoquin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2013-2020 for Eoquin

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 2

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 8

3 Baldder Cancer Disease: Market Characterization 9
3.1 Bladder Cancer Disease Market 9
3.2 Bladder Cancer Disease Market Forecasts and CAGR 9
3.3 Drivers for the Bladder Cancer Disease Market 9
3.3.1 High Prevalence 10
3.3.2 High Incidence 10
3.3.3 High Survival Rate 11
3.3.4 High lifetime costs 11

4 TNM Classification of bladder cancer 12
4.1 American Urological Association 12

5 EOquin(Apaziquone) 16
5.1 Introduction 16
5.2 Mechanism of Action 16
5.3 Clinical Studies 17
5.3.1 Clinical History of EOquin 17
5.4 Fast Track Designation 18
5.5 Milestone payment from Allergan Pharmaceuticals 18
5.6 Sales drivers 18
5.6.1 Bladder Cancer Market 18
5.6.2 Better Efficacy 19
5.6.3 Helps Reducing Recurrence 19
5.7 Drug Evaluation 19
5.7.1 Drug Risk Benefit Score 19
5.7.2 Intensity of Competition 20
5.8 Sales forecast 21
5.8.1 Target patient Pool of EOquin 21
5.8.2 Dosing 22
5.8.3 Market Penetration 22
5.8.4 Annual Cost of Therapy 22
5.8.5 Sales Projections of EOquin 22

6 Bladder Cancer Market: Appendix 23
6.1 Market Definitions 23
6.2 List of Abberiviations 23
6.3 Research Methodology 23
6.3.1 Coverage 23
6.3.2 Secondary Research 23
6.3.3 Forecasting 24
6.3.4 Number of Patients Approved to take the Drug 24
6.3.5 Net Penetration of Drug 24
6.3.6 Net Annual Dosing 24
6.3.7 Annual Cost of Therapy 25
6.3.8 Primary Research 25
6.3.9 Expert Panels 25
6.4 Contact Us 25
6.5 Disclaimer 25
6.6 Sources 25

 


Table 1: Bladder Cancer Incidences & Mortality 5
Table 2: Bladder Cancer, Global, Market Forecast ($bn), 20092020 9
Table 3: Drug Risk Benefit Score of EOquin 20


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 6
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 7
Figure 5: Smoking Consumption Curve, US 7
Figure 6: Forecasted Global Bladder Cancer Market ($bn), 2009-2020 9
Figure 7: All Cancer Incidence Worldwide 10
Figure 8: Bladder Cancer Incidence Worldwide 10
Figure 9: Broad Classification of Bladder Cancer 12
Figure 10: Classification of NMI Bladder Cancer 12
Figure 11: Detailed TNM Classifications 13
Figure 12: TNM staging of urothelial tract cancers: Stage I to Stage IV 14
Figure 13: Classification of NMI Bladder Cancer 14
Figure 15: Drug Model Diagram of EOquin 21
Figure 16: Global Forecasted Sales of EOquin ($mn), 2013-2020 23
Figure 17: Distribution of EOquin sales in Major Countries, 2020 23